APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 3
MARCH 2005



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2005

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Cumulative Supplement 3

March 2005

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

CUMULATIVE SUPPLEMENT 3
March 2005

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of

the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
FUJISAWA HEALTHCARE (FUJISAWA HLTHCARE)	ASTELLAS PHARMA US INC (ASTELLAS)
SHIRE LABORATORIES INC (SHIRE LABS)	SHIRE DEVELOPMENT INC (SHIRE)
SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)	SHIRE DEVELOPMENT INC (SHIRE)
YAMANOUCHI PHARMA AMERICA INC (YAMANOUCHI)	ASTELLAS PHARMA US INC (ASTELLAS)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

By April, the 25th edition and current monthly supplement will be available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the EOB Preface. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2004	MAR 2005	JUN 2005	SEP 2005
DRUG PRODUCTS LISTED	11082	11184		
SINGLE SOURCE	2427 (21.9%)	2437 (21.8%)		
MULTISOURCE	8547 (77.1%)	8637 (77.2%)		
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	8428 (75.4%)		
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	209 (1.9%)		
EXCEPTIONS[1]	108 (1.0%)	110 (1.0%)		
NEW MOLECULAR ENTITIES APPROVED	9	2		
NUMBER OF APPLICANTS	625	631		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, APAP, AND CAFFEINE

	AB		WATSON LABS	325MG;50MG;40MG	N89536	001	Feb 16, 1988	Feb	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

>A>			ACETAMINOPHEN AND TRAMADOL HCL						
>A>	AB		KALI LABS	325MG;37.5MG	N76475	001	Apr 21, 2005	Mar	NEWA
			ULTRACET						
>D>		+	ORTHO MCNEIL PHARM	325MG;37.5MG	N21123	001	Aug 15, 2001	Mar	CFTG
>A>	AB	+		325MG;37.5MG	N21123	001	Aug 15, 2001	Mar	CFTG

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

	AT	+	MORTON GROVE	2%	N40166	001	Jul 26, 1996	Jan	CRLD
	AT		VINTAGE	2%	N40607	001	Feb 24, 2005	Feb	NEWA
			VOSOL						
			@ MEDPOINTE PHARM HLC	2%	N12179	001		Jan	DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

>D>		+	CELLTECH PHARMS	8MG;60MG	N19806	001	Mar 25, 1994	Mar	CAHN
>A>		+	UCB	8MG;60MG	N19806	001	Mar 25, 1994	Mar	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	AB		COPLEY PHARM	200MG	N74914	001	Nov 26, 1997	Mar	CAHN
>A>	AB		TEVA PHARMS	200MG	N74914	001	Nov 26, 1997	Mar	CAHN

TABLET; ORAL

ACYCLOVIR

>D>	AB		COPLEY PHARM	400MG	N75021	001	Mar 18, 1998	Mar	CAHN
>D>	AB			800MG	N75021	002	Mar 18, 1998	Mar	CAHN
>A>	AB		TEVA PHARMS	400MG	N75021	001	Mar 18, 1998	Mar	CAHN
>A>	AB			800MG	N75021	002	Mar 18, 1998	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

			@ ABBOTT	EQ 50MG BASE/ML	N75114	001	Jul 26, 1999	Feb	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

	AN	+	DEY	EQ 0.083% BASE	N72652	001	Feb 21, 1992	Jan	CRLD

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

			SCHWARZ PHARMA	0.25MG	N21726	001	Jan 19, 2005	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

		SCHWARZ PHARMA	0.5MG	N21726	002	Jan 19, 2005	Jan	NEWA
			1MG	N21726	003	Jan 19, 2005	Jan	NEWA
	+		2MG	N21726	004	Jan 19, 2005	Jan	NEWA

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

>D>	AA	COPLEY PHARM	50MG/5ML	N73115	001	Aug 23, 1991	Mar	CAHN
>A>	AA	TEVA PHARMS	50MG/5ML	N73115	001	Aug 23, 1991	Mar	CAHN

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN 7%

>D>		@ HOSPIRA	7% (7GM/100ML)	N17673	002		Mar	CMFD
>A>			7% (7GM/100ML)	N17673	002		Mar	CMFD

AMINOSYN 8.5%

>D>		@ HOSPIRA	8.5% (8.5GM/100ML)	N17673	004		Mar	CMFD
>A>			8.5% (8.5GM/100ML)	N17673	004		Mar	CMFD

AMIODARONE

INJECTABLE; INTRAVENOUS
AMIODARONE HCL

>A>	AP	APOTEX	50MG/ML	N77161	001	Apr 20, 2005	Mar	NEWA

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL

>D>	AP	AM PHARM PARTNERS	50MG/ML	N75761	001	Oct 15, 2002	Mar	CRLD
>A>	AP	+	50MG/ML	N75761	001	Oct 15, 2002	Mar	CRLD
>D>	AP	APOTEX	50MG/ML	N76394	001	Apr 25, 2003	Mar	CRLD
>A>	AP	+	50MG/ML	N76394	001	Apr 25, 2003	Mar	CRLD
>D>	AP	BEDFORD	50MG/ML	N76018	001	Oct 15, 2002	Mar	CRLD
>A>	AP	+	50MG/ML	N76018	001	Oct 15, 2002	Mar	CRLD
>D>	AP	BEDFORD LABS	50MG/ML	N76299	001	Oct 24, 2002	Mar	CRLD
>A>	AP	+	50MG/ML	N76299	001	Oct 24, 2002	Mar	CRLD
>D>	AP	BEN VENUE	50MG/ML	N76088	001	Oct 15, 2002	Mar	CRLD
>A>	AP	+	50MG/ML	N76088	001	Oct 15, 2002	Mar	CRLD
>D>	AP	BIONICHE (CANADA)	50MG/ML	N76217	001	Oct 15, 2002	Mar	CRLD
>A>	AP	+	50MG/ML	N76217	001	Oct 15, 2002	Mar	CRLD
>D>	AP	MAYNE PHARMA USA	50MG/ML	N76108	001	Oct 15, 2002	Mar	CRLD
>A>	AP	+	50MG/ML	N76108	001	Oct 15, 2002	Mar	CRLD
>D>	AP	SICOR PHARMS	50MG/ML	N76163	001	Sep 05, 2003	Mar	CRLD
>A>	AP	+	50MG/ML	N76163	001	Sep 05, 2003	Mar	CRLD

TABLET; ORAL
AMIODARONE HCL

>A>	AB	AUROSAL PHARMS	200MG	N77069	001	Apr 08, 2005	Mar	NEWA
>A>	AB		400MG	N77069	002	Apr 08, 2005	Mar	NEWA
>D>	AB	COPLEY PHARM	200MG	N74739	001	Nov 30, 1998	Mar	CAHN
>D>		TARO	100MG	N75424	002	Dec 18, 2002	Mar	CTEC
>A>	AB		100MG	N75424	002	Dec 18, 2002	Mar	CTEC
>A>	AB	TEVA PHARMS	200MG	N74739	001	Nov 30, 1998	Mar	CAHN

PACERONE

>A>	AB	UPSHER SMITH	100MG	N75135	002	Apr 12, 2005	Mar	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	HIKMA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65191	002	Jan 25, 2005	Jan	NEWA
	AB		400MG/5ML;EQ 57MG BASE/5ML	N65191	001	Jan 25, 2005	Jan	NEWA

TABLET, CHEWABLE; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	TEVA	200MG;EQ 28.5MG BASE	N65205	001	Feb 09, 2005	Jan	NEWA
	AB		400MG;EQ 57MG BASE	N65205	002	Feb 09, 2005	Jan	NEWA

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

	AP	INSTITUTO BIOCHEMICO	EQ 125MG BASE/VIAL	N62797	001	Jul 12, 1993	Jan	CMFD
	AP		EQ 2GM BASE/VIAL	N62797	002	Jul 12, 1993	Jan	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN

>D>		SHIRE	EQ 0.5MG BASE	N20333	001	Mar 14, 1997	Mar	CFTG
>A>	AB		EQ 0.5MG BASE	N20333	001	Mar 14, 1997	Mar	CFTG
>D>	+		EQ 1MG BASE	N20333	002	Mar 14, 1997	Mar	CFTG
>A>	AB +		EQ 1MG BASE	N20333	002	Mar 14, 1997	Mar	CFTG

>A> ANAGRELIDE HCL

>A>	AB	BARR	EQ 0.5MG BASE	N76530	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76530	002	Apr 18, 2005	Mar	NEWA
>A>	AB	EON	EQ 0.5MG BASE	N76683	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76683	002	Apr 18, 2005	Mar	NEWA
>A>	AB	IMPAX LABS	EQ 0.5MG BASE	N76910	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76910	002	Apr 18, 2005	Mar	NEWA
>A>	AB	IVAX PHARMS	EQ 0.5MG BASE	N76468	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76468	002	Apr 18, 2005	Mar	NEWA
>A>	AB	MYLAN	EQ 0.5MG BASE	N76811	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76811	002	Apr 18, 2005	Mar	NEWA
>A>	AB	ROXANE	EQ 0.5MG BASE	N76489	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76489	002	Apr 18, 2005	Mar	NEWA
>A>	AB	WATSON LABS	EQ 0.5MG BASE	N76417	001	Apr 18, 2005	Mar	NEWA
>A>	AB		EQ 1MG BASE	N76417	002	Apr 18, 2005	Mar	NEWA

ATENOLOL

TABLET; ORAL
ATENOLOL

>D>	AB	COPLEY PHARM	50MG	N74120	001	Feb 24, 1995	Mar	CAHN
>D>	AB		100MG	N74120	002	Feb 24, 1995	Mar	CAHN
>D>		MYLAN	25MG	N73457	002	Apr 26, 1999	Mar	CTEC
>A>	AB		25MG	N73457	002	Apr 26, 1999	Mar	CTEC
>A>	AB	TEVA PHARMS	50MG	N74120	001	Feb 24, 1995	Mar	CAHN
>A>	AB		100MG	N74120	002	Feb 24, 1995	Mar	CAHN
	AB	ZYDUS PHARMS USA	25MG	N76900	001	Jan 28, 2005	Jan	NEWA
	AB		50MG	N76900	002	Jan 28, 2005	Jan	NEWA
	AB		100MG	N76900	003	Jan 28, 2005	Jan	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

		LILLY	80MG	N21411	007	Feb 14, 2005	Feb	NEWA
			100MG	N21411	008	Feb 14, 2005	Feb	NEWA

>D> BENZYL PENICILLOYL-POLYLYSINE

>D> INJECTABLE; INJECTION

>D> PRE-PEN

>D>	+	HOLLISTER STIER LABS	60UMOLAR	N50114	001		Mar	DISC
>A>		@	60UMOLAR	N50114	001		Mar	DISC

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB	COPLEY PHARM	EQ 0.05% BASE	N71882	001	Jun 06, 1988	Mar	CAHN
>A>	AB	TEVA PHARMS	EQ 0.05% BASE	N71882	001	Jun 06, 1988	Mar	CAHN

OINTMENT; TOPICAL

ALPHATREX

		@ SAVAGE LABS	EQ 0.05% BASE	N19143	001	Sep 04, 1984	Jan	DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

>D>	AB	COPLEY PHARM	EQ 0.1% BASE	N71883	001	Apr 22, 1988	Mar	CAHN
>A>	AB	TEVA PHARMS	EQ 0.1% BASE	N71883	001	Apr 22, 1988	Mar	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

>D>	AB	COPLEY PHARM	5MG	N75644	001	Jun 26, 2001	Mar	CAHN
>D>	AB		10MG	N75644	002	Jun 26, 2001	Mar	CAHN
>A>	AB	TEVA PHARMS	5MG	N75644	001	Jun 26, 2001	Mar	CAHN
>A>	AB		10MG	N75644	002	Jun 26, 2001	Mar	CAHN

>A> BROMFENAC SODIUM

>A> SOLUTION/DROPS; OPHTHALMIC

>A> XIBROM

>A>	+	ISTA PHARMS	0.09%	N21664	001	Mar 24, 2005	Mar	NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

>A>	AB	MYLAN	EQ 5MG BASE	N77226	001	Apr 04, 2005	Mar	NEWA

PARLODEL

>D>	+	NOVARTIS	EQ 5MG BASE	N17962	002	Mar 01, 1982	Mar	CTEC
>A>	AB +		EQ 5MG BASE	N17962	002	Mar 01, 1982	Mar	CTEC

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

	AP	BEDFORD	EQ 0.3MG BASE/ML	N76931	001	Mar 02, 2005	Feb	NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

BR	G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CMFD

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>D> AB	COPLEY PHARM	12.5MG	N74462	001	Feb 13, 1996	Mar	CAHN
>D> AB		25MG	N74462	002	Feb 13, 1996	Mar	CAHN
>D> AB		50MG	N74462	003	Feb 13, 1996	Mar	CAHN
>D> AB		100MG	N74462	004	Feb 13, 1996	Mar	CAHN
>A> AB	TEVA PHARMS	12.5MG	N74462	001	Feb 13, 1996	Mar	CAHN
>A> AB		25MG	N74462	002	Feb 13, 1996	Mar	CAHN
>A> AB		50MG	N74462	003	Feb 13, 1996	Mar	CAHN
>A> AB		100MG	N74462	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

>D> AB	TARO	100MG/5ML	N75875	001	Dec 21, 2000	Mar	DISC
>A>	@	100MG/5ML	N75875	001	Dec 21, 2000	Mar	DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>A> AP	EON	50MG/VIAL	N76959	001	Mar 18, 2005	Mar	NEWA
>A> AP		150MG/VIAL	N76959	002	Mar 18, 2005	Mar	NEWA
>A> AP		450MG/VIAL	N76959	003	Mar 18, 2005	Mar	NEWA

CEFACLOR

CAPSULE; ORAL

>D>	CECLOR							
>D> AB	LILLY	EQ 250MG BASE	N50521	001		Mar	DISC
>A>	@	EQ 250MG BASE	N50521	001		Mar	DISC
>D> AB +		EQ 500MG BASE	N50521	002		Mar	DISC
>A>	@	EQ 500MG BASE	N50521	002		Mar	DISC
	CEFACLOR							
>D> AB	RANBAXY	EQ 500MG BASE	N64156	002	Aug 28, 1997	Mar	CRLD
>A> AB +		EQ 500MG BASE	N64156	002	Aug 28, 1997	Mar	CRLD

FOR SUSPENSION; ORAL

CECLOR

>D> AB +	CEPH INTL	EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Mar	CRLD
>A> AB		EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Mar	CRLD
>D> AB	LILLY	EQ 125MG BASE/5ML	N50522	001		Mar	DISC
>A>	@	EQ 125MG BASE/5ML	N50522	001		Mar	DISC
>D> AB +		EQ 250MG BASE/5ML	N50522	002		Mar	DISC
>A>	@	EQ 250MG BASE/5ML	N50522	002		Mar	DISC
	CEFACLOR							
>D> AB	RANBAXY	EQ 375MG BASE/5ML	N64155	001	Oct 02, 1997	Mar	CRLD
>A> AB +		EQ 375MG BASE/5ML	N64155	001	Oct 02, 1997	Mar	CRLD

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

>D>	AP		AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64169	001	Aug 14, 1998	Mar	CRLD
>A>	AP	+		EQ 500MG BASE/VIAL	N64169	001	Aug 14, 1998	Mar	CRLD
>D>	AP			EQ 1GM BASE/VIAL	N64169	002	Aug 14, 1998	Mar	CRLD
>A>	AP	+		EQ 1GM BASE/VIAL	N64169	002	Aug 14, 1998	Mar	CRLD
>D>	AP			EQ 10GM BASE/VIAL	N64170	001	Mar 18, 1998	Mar	CRLD
>A>	AP	+		EQ 10GM BASE/VIAL	N64170	001	Mar 18, 1998	Mar	CRLD

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

>D>	AB		APOTHECON	EQ 250MG BASE	N63186	001	Dec 30, 1994	Mar	DISC
>A>			@	EQ 250MG BASE	N63186	001	Dec 30, 1994	Mar	DISC
>D>	AB			EQ 500MG BASE	N63186	002	Dec 30, 1994	Mar	DISC
>A>			@	EQ 500MG BASE	N63186	002	Dec 30, 1994	Mar	DISC
	AB		BELCHER	EQ 250MG BASE	N62713	001	Jul 15, 1988	Jan	CAHN
	AB			EQ 500MG BASE	N62713	002	Jul 15, 1988	Jan	CAHN
	AB		SUN PHARM INDS (IN)	EQ 250MG BASE	N62791	001	Jun 11, 1987	Jan	CAHN
	AB			EQ 500MG BASE	N62791	002	Jun 11, 1987	Jan	CAHN
	AB		YUNG SHIN PHARM	EQ 250MG BASE	N65152	001	Feb 24, 2005	Feb	NEWA
	AB			EQ 500MG BASE	N65152	002	Feb 24, 2005	Feb	NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

>D>		+	CELLTECH PHARMS	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	CAHN
>A>		+	UCB	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX

>D>		+	CELLTECH PHARMS	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N19111	001	Dec 31, 1987	Mar	CAHN
>A>		+	UCB	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N19111	001	Dec 31, 1987	Mar	CAHN

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>D>	AB		COPLEY PHARM	EQ 4GM RESIN/PACKET	N74554	001	Oct 02, 1996	Mar	CAHN
>D>	AB			EQ 4GM RESIN/SCOOPFUL	N74554	002	Oct 02, 1996	Mar	CAHN
>A>	AB		TEVA PHARMS	EQ 4GM RESIN/PACKET	N74554	001	Oct 02, 1996	Mar	CAHN
>A>	AB			EQ 4GM RESIN/SCOOPFUL	N74554	002	Oct 02, 1996	Mar	CAHN

CHOLESTYRAMINE LIGHT

>D>	AB		COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555	001	Sep 30, 1998	Mar	CAHN
>D>	AB			EQ 4GM RESIN/SCOOPFUL	N74555	002	Sep 30, 1998	Mar	CAHN
>A>	AB		TEVA PHARMS	EQ 4GM RESIN/PACKET	N74555	001	Sep 30, 1998	Mar	CAHN
>A>	AB			EQ 4GM RESIN/SCOOPFUL	N74555	002	Sep 30, 1998	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

>A>	AB		TARO	0.77%	N76790	001	Apr 12, 2005	Mar	NEWA

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	COREPHARMA	50MG	N77150	001	Mar 11, 2005	Feb	NEWA
AB	IVAX PHARMS	100MG	N77020	002	Mar 01, 2005	Feb	NEWA

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HCL

>D> AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859	001	Jul 09, 1998	Mar	CAHN
>A> AA	TEVA PHARMS	EQ 300MG BASE/5ML	N74859	001	Jul 09, 1998	Mar	CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN

AT	HITECH PHARMA	EQ 0.3% BASE	N76673	001	Jan 21, 2005	Jan	NEWA

TABLET; ORAL

CIPROFLOXACIN

AB	COBALT	EQ 100MG BASE	N76794	001	Feb 10, 2005	Jan	NEWA
AB	SANDOZ	EQ 100MG BASE	N75939	001	Mar 03, 2005	Feb	NEWA
AB	TARO	EQ 100MG BASE	N76912	001	Feb 18, 2005	Jan	NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	N77039	001	Feb 03, 2005	Jan	NEWA
AB		EQ 20MG BASE	N77039	002	Feb 03, 2005	Jan	NEWA
AB		EQ 40MG BASE	N77039	003	Feb 03, 2005	Jan	NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

	RANBAXY	1GM	N65210	001	Jan 26, 2005	Jan	NEWA

TABLET; ORAL

CLARITHROMYCIN

AB	GENPHARM	250MG	N65195	001	Mar 11, 2005	Feb	NEWA
AB		500MG	N65195	002	Mar 11, 2005	Feb	NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

>D> AA	COPLEY PHARM	EQ 0.5MG BASE/5ML	N73095	001	Apr 21, 1992	Mar	CAHN
>A> AA	TEVA PHARMS	EQ 0.5MG BASE/5ML	N73095	001	Apr 21, 1992	Mar	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	ZYDUS PHARMS USA	EQ 75MG BASE	N65217	001	Jan 31, 2005	Jan	NEWA
AB		EQ 150MG BASE	N65217	002	Jan 31, 2005	Jan	NEWA
AB		EQ 300MG BASE	N65217	003	Jan 31, 2005	Jan	NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

>D>	@ HOSPIRA	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	Mar	CMFD

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

>A>	AP	HOSPIRA	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	Mar	CMFD

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

>D>	AB1	COPLEY PHARM	0.05%	N74087	001	Feb 16, 1994	Mar	CAHN
>A>	AB1	TEVA PHARMS	0.05%	N74087	001	Feb 16, 1994	Mar	CAHN

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

>D>	AB	COPLEY PHARM	0.05%	N74089	001	Feb 16, 1994	Mar	CAHN
>A>	AB	TEVA PHARMS	0.05%	N74089	001	Feb 16, 1994	Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE

+		TARO	1%	N72640	001	Aug 31, 1993	Feb	CRLD

LOTRIMIN

@		SCHERING PLOUGH	1%	N17619	001		Feb	DISC

MYCELEX

@		BAYER PHARMS	1%	N18183	001		Feb	DISC

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

>D>	+	CELLTECH PHARMS	100MG/5ML	N20479	001	Feb 29, 1996	Mar	CAHN
>A>	+	UCB	100MG/5ML	N20479	001	Feb 29, 1996	Mar	CAHN

CYANOCOBALAMIN

SPRAY, METERED; NASAL
NASCOBAL

+		NASTECH PHARM	0.5MG/SPRAY	N21642	001	Jan 31, 2005	Jan	NEWA
+		QUESTCOR PHARMS	0.5MG/SPRAY	N21642	001	Jan 31, 2005	Feb	CAHN

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE

>A>	AB1	IVAX PHARMS	25MG	N65110	003	Mar 29, 2005	Mar	NEWA
>A>	AB1		50MG	N65110	001	Mar 29, 2005	Mar	NEWA
>A>	AB1		100MG	N65110	002	Mar 29, 2005	Mar	NEWA

GENGRAF

>D>	BX	ABBOTT	50MG	N65003	002	May 12, 2000	Mar	CTEC
>A>	AB1		50MG	N65003	002	May 12, 2000	Mar	CTEC

SOLUTION; ORAL
CYCLOSPORINE

>A>	AB1	IVAX PHARMS	100MG/ML	N65078	001	Mar 25, 2005	Mar	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

@		ABC HOLDING	4MG	N88212	001	May 26, 1983	Feb	DISC

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN

+	PHARMACIA AND UPJOHN	7,500 IU/0.3ML	N20287	005	Apr 04, 2002	Jan	NEWA

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM

AB		PROCTER AND GAMBLE	25MG	N17443	001		Feb	CFTG
AB			50MG	N17443	003		Feb	CFTG
AB	+		100MG	N17443	002		Feb	CFTG

DANTROLENE SODIUM

AB		IMPAX LABS	25MG	N76856	001	Mar 01, 2005	Feb	NEWA
AB			50MG	N76856	002	Mar 01, 2005	Feb	NEWA
AB			100MG	N76856	003	Mar 01, 2005	Feb	NEWA

>D> DESIRUDIN

>D> INJECTABLE; SUBCUTANEOUS
>D> IPRIVASK

>D>	+	CANYON	15MG/VIAL	N21271	001	Apr 04, 2003	Mar	CAIN

>A> DESIRUDIN RECOMBINANT

>A> INJECTABLE; SUBCUTANEOUS
>A> IPRIVASK

>A>	+	CANYON	15MG/VIAL	N21271	001	Apr 04, 2003	Mar	CAIN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

>A> TABLET, EXTENDED RELEASE; ORAL
>A> CLARINEX D 24 HOUR

>A>	+	SCHERING	5MG;240MG	N21605	001	Mar 03, 2005	Mar	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB		APOTEX	0.01MG/SPRAY	N76703	001	Jan 27, 2005	Jan	NEWA

DESONIDE

CREAM; TOPICAL
DESONIDE

>D>	AB	COPLEY PHARM	0.05%	N74027	001	Sep 28, 1992	Mar	CAHN
>A>	AB	TEVA PHARMS	0.05%	N74027	001	Sep 28, 1992	Mar	CAHN

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

>D>		+ PAR PHARM	0.25MG	N88149	001	Apr 28, 1983	Mar	CRLD
>A>			0.25MG	N88149	001	Apr 28, 1983	Mar	CRLD
>D>	BP	+ ROXANE	1.5MG	N84610	001		Mar	CRLD
>A>	BP		1.5MG	N84610	001		Mar	CRLD

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 50% IN PLASTIC CONTAINER

>D>		@ HOSPIRA	500MG/ML	N19445	001	Jun 03, 1986	Mar	CMFD
>A>	AP		500MG/ML	N19445	001	Jun 03, 1986	Mar	CMFD

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB		COPLEY PHARM	25MG	N74459	001	Jun 25, 1997	Mar	CAHN
>D>	AB			50MG	N74459	002	Jun 25, 1997	Mar	CAHN
>D>	AB			75MG	N74459	003	Jun 25, 1997	Mar	CAHN
>A>	AB		TEVA PHARMS	25MG	N74459	001	Jun 25, 1997	Mar	CAHN
>A>	AB			50MG	N74459	002	Jun 25, 1997	Mar	CAHN
>A>	AB			75MG	N74459	003	Jun 25, 1997	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

BENTYL

>D>		+	AXCAN SCANDIPHARM	10MG/5ML	N07961	002	Oct 15, 1984	Mar	CTEC
>A>	AA	+		10MG/5ML	N07961	002	Oct 15, 1984	Mar	CTEC

>A> DICYCLOMINE HCL

>A>	AA		MIKART	10MG/5ML	N40169	001	Mar 24, 2005	Mar	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HCL

		@	ABC HOLDING	25MG	N88267	001	Aug 25, 1983	Feb	DISC
		@		25MG	N88268	001	Aug 25, 1983	Feb	DISC

TENUATE

		+	AVENTIS PHARMS	25MG	N11722	002		Feb	CTEC

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

>D>	AP	+	BIOVAIL	5MG/ML	N20027	001	Oct 24, 1991	Mar	CAHN
>D>		+		25MG/VIAL	N20027	003	Aug 18, 1995	Mar	CAHN
>A>	AP	+	BIOVAIL LABS INTL	5MG/ML	N20027	001	Oct 24, 1991	Mar	CAHN
>A>		+		25MG/VIAL	N20027	003	Aug 18, 1995	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

>D>			BIOVAIL	120MG	N21392	001	Feb 06, 2003	Mar	CAHN
>D>				180MG	N21392	002	Feb 06, 2003	Mar	CAHN
>D>				240MG	N21392	003	Feb 06, 2003	Mar	CAHN
>D>				300MG	N21392	004	Feb 06, 2003	Mar	CAHN
>D>				360MG	N21392	005	Feb 06, 2003	Mar	CAHN
>D>		+		420MG	N21392	006	Feb 06, 2003	Mar	CAHN
>A>			BIOVAIL LABS INTL	120MG	N21392	001	Feb 06, 2003	Mar	CAHN
>A>				180MG	N21392	002	Feb 06, 2003	Mar	CAHN
>A>				240MG	N21392	003	Feb 06, 2003	Mar	CAHN
>A>				300MG	N21392	004	Feb 06, 2003	Mar	CAHN
>A>				360MG	N21392	005	Feb 06, 2003	Mar	CAHN
>A>		+		420MG	N21392	006	Feb 06, 2003	Mar	CAHN

TABLET; ORAL

CARDIZEM

>D>	AB		BIOVAIL	30MG	N18602	001	Nov 05, 1982	Mar	CAHN
>D>	AB			60MG	N18602	002	Nov 05, 1982	Mar	CAHN
>D>	AB			90MG	N18602	003	Dec 08, 1986	Mar	CAHN
>D>	AB	+		120MG	N18602	004	Dec 08, 1986	Mar	CAHN
>A>	AB		BIOVAIL LABS INTL	30MG	N18602	001	Nov 05, 1982	Mar	CAHN
>A>	AB			60MG	N18602	002	Nov 05, 1982	Mar	CAHN

TABLET; ORAL
CARDIZEM

>A>	AB		BIOVAIL LABS INTL	90MG	N18602	003	Dec 08, 1986	Mar	CAHN
>A>	AB	+		120MG	N18602	004	Dec 08, 1986	Mar	CAHN

DILTIAZEM HCL

>D>	AB		COPLEY PHARM	30MG	N74067	001	Nov 05, 1992	Mar	CAHN
>D>	AB			60MG	N74067	002	Nov 05, 1992	Mar	CAHN
>D>	AB			90MG	N74067	003	Nov 05, 1992	Mar	CAHN
>D>	AB			120MG	N74067	004	Nov 05, 1992	Mar	CAHN
>A>	AB		TEVA PHARMS	30MG	N74067	001	Nov 05, 1992	Mar	CAHN
>A>	AB			60MG	N74067	002	Nov 05, 1992	Mar	CAHN
>A>	AB			90MG	N74067	003	Nov 05, 1992	Mar	CAHN
>A>	AB			120MG	N74067	004	Nov 05, 1992	Mar	CAHN

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL
CARDURA XL

			PFIZER	EQ 4MG BASE	N21269	001	Feb 22, 2005	Feb	NEWA
		+		EQ 8MG BASE	N21269	002	Feb 22, 2005	Feb	NEWA

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

>D>	AA		COPLEY PHARM	EQ 10MG BASE/ML	N71609	001	Nov 09, 1987	Mar	CAHN
>A>	AA		TEVA PHARMS	EQ 10MG BASE/ML	N71609	001	Nov 09, 1987	Mar	CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

>A>	AB		PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	NEWA
>D>		+	RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC
>A>	AB			EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

			@ APOTHECON	2.5MG	N75583	001	Aug 22, 2000	Feb	DISC
			@	5MG	N75583	002	Aug 22, 2000	Feb	DISC
			@	10MG	N75583	003	Aug 22, 2000	Feb	DISC
			@	20MG	N75583	004	Aug 22, 2000	Feb	DISC

VASOTEC

>D>	AB		BIOVAIL	2.5MG	N18998	005	Jul 26, 1988	Mar	CAHN
>D>	AB			5MG	N18998	001	Dec 24, 1985	Mar	CAHN
>D>	AB			10MG	N18998	002	Dec 24, 1985	Mar	CAHN
>D>	AB	+		20MG	N18998	003	Dec 24, 1985	Mar	CAHN
>A>	AB		BIOVAIL LABS INTL	2.5MG	N18998	005	Jul 26, 1988	Mar	CAHN
>A>	AB			5MG	N18998	001	Dec 24, 1985	Mar	CAHN
>A>	AB			10MG	N18998	002	Dec 24, 1985	Mar	CAHN
>A>	AB	+		20MG	N18998	003	Dec 24, 1985	Mar	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC

>D>	AB		BIOVAIL	5MG;12.5MG	N19221	003	Jul 12, 1995	Mar	CAHN
>D>	AB	+		10MG;25MG	N19221	001	Oct 31, 1986	Mar	CAHN
>A>	AB		BIOVAIL LABS INTL	5MG;12.5MG	N19221	003	Jul 12, 1995	Mar	CAHN

TABLET; ORAL
VASERETIC
>A> AB + BIOVAIL LABS INTL 10MG;25MG N19221 001 Oct 31, 1986 Mar CAHN

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC
>D> AP + BIOVAIL 1.25MG/ML N19309 001 Feb 09, 1988 Mar CAHN
>A> AP + BIOVAIL LABS INTL 1.25MG/ML N19309 001 Feb 09, 1988 Mar CAHN

>A> ENTECAVIR

>A> SOLUTION; ORAL
>A> BARACLUDE
>A> + BRISTOL MYERS SQUIBB 0.05MG/ML N21798 001 Mar 29, 2005 Mar NEWA

>A> TABLET; ORAL
>A> BARACLUDE
>A> BRISTOL MYERS SQUIBB 0.5MG N21797 001 Mar 29, 2005 Mar NEWA
>A> + 1MG N21797 002 Mar 29, 2005 Mar NEWA

EPINEPHRINE

INJECTABLE; IM-SC
TWINJECT 0.30
+ HOLLISTER STIER LABS EQ 0.3MG /DELIVERY N20800 001 May 30, 2003 Feb CTNA

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYMAX
AT MERZ PHARMS 2% N62508 002 Jul 11, 1985 Jan CAHN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
@ BARR EQ 250MG BASE N62162 002 Feb DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM
ASTRAZENECA EQ 20MG BASE N21153 001 Feb 20, 2001 Jan CRLD

>A> ESOMEPRAZOLE SODIUM

>A> INJECTABLE; INTRAVENOUS
>A> NEXIUM IV
>A> + ASTRAZENECA 20MG/VIAL N21689 001 Mar 31, 2005 Mar NEWA
>A> + 40MG/VIAL N21689 002 Mar 31, 2005 Mar NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
AB2 + BERLEX 0.025MG/24HR N20375 004 Mar 05, 1999 Jan CFTG
AB2 + 0.075MG/24HR N20375 003 Mar 23, 1998 Jan CFTG
ESCLIM
@ WOMEN FIRST HLTHCARE 0.025MG/24HR N20847 001 Aug 04, 1998 Jan DISC
@ 0.0375MG/24HR N20847 002 Aug 04, 1998 Jan DISC
@ 0.05MG/24HR N20847 003 Aug 04, 1998 Jan DISC
@ 0.075MG/24HR N20847 004 Aug 04, 1998 Jan DISC
@ 0.1MG/24HR N20847 005 Aug 04, 1998 Jan DISC

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	0.025MG/24HR	N75182	003	Jan 26, 2005	Jan	NEWA
AB2			0.075MG/24HR	N75182	002	Jan 26, 2005	Jan	NEWA

VIVELLE

		@ NOVARTIS	0.025MG/24HR	N20323	005	Aug 16, 2000	Jan	DISC
AB1			0.05MG/24HR	N20323	002	Oct 28, 1994	Jan	CRLD
AB1			0.1MG/24HR	N20323	004	Oct 28, 1994	Jan	CRLD

VIVELLE-DOT

BX	+	NOVARTIS	0.025MG/24HR	N20538	009	May 03, 2002	Jan	CRLD
BX	+		0.0375MG/24HR	N20538	005	Jan 08, 1999	Jan	CRLD
AB1	+		0.05MG/24HR	N20538	006	Jan 08, 1999	Jan	CRLD
BX	+		0.075MG/24HR	N20538	007	Jan 08, 1999	Jan	CRLD
AB1	+		0.1MG/24HR	N20538	008	Jan 08, 1999	Jan	CRLD

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

>A>		@ DURAMED	0.3MG	N21443	001	Dec 20, 2004	Mar	DISC
>A>		@	0.45MG	N21443	002	Dec 20, 2004	Mar	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

>D>	AB	+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Mar	CTEC
>A>		+		0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Mar	CTEC

NORTREL 7/7/7

>D>	AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478	001	Aug 30, 2002	Mar	CTEC
>A>			0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478	001	Aug 30, 2002	Mar	CTEC

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

>D>	AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042	001	Sep 24, 1991	Mar	CTEC
>A>			0.035MG,0.035MG;0.5MG,1MG	N71042	001	Sep 24, 1991	Mar	CTEC

ORTHO-NOVUM 10/11-28

>D>	AB	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	CRLD
>A>	AB	+	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	CRLD

ORTHO-NOVUM 7/14-28

		@ ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N19004	002	Apr 04, 1984	Feb	DISC

OVCON-35

>D>	AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar	CRLD
>A>	AB		0.035MG;0.4MG	N17716	001		Mar	CRLD

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

>D>	AA	COPLEY PHARM	250MG/5ML	N81306	001	Jul 30, 1993	Mar	CAHN
>A>	AA	TEVA PHARMS	250MG/5ML	N81306	001	Jul 30, 1993	Mar	CAHN

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

AP		SABEX 2002	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

		DURAGESIC-100						
	AB	ALZA	100UGM/HR	N19813	001	Aug 07, 1990	Jan	CFTG
		DURAGESIC-12						
		ALZA	12.5UGM/HR	N19813	005	Feb 04, 2005	Feb	NEWA
		DURAGESIC-25						
	AB +	ALZA	25UGM/HR	N19813	004	Aug 07, 1990	Jan	CFTG
		DURAGESIC-50						
	AB	ALZA	50UGM/HR	N19813	003	Aug 07, 1990	Jan	CFTG
		DURAGESIC-75						
	AB	ALZA	75UGM/HR	N19813	002	Aug 07, 1990	Jan	CFTG
		FENTANYL						
	AB	MYLAN TECHNOLOGIES	25UGM/HR	N76258	001	Jan 28, 2005	Jan	NEWA
	AB		50UGM/HR	N76258	002	Jan 28, 2005	Jan	NEWA
	AB		75UGM/HR	N76258	003	Jan 28, 2005	Jan	NEWA
	AB		100UGM/HR	N76258	004	Jan 28, 2005	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		ALLEGRA-D 12 HOUR						
>D>	+	AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Mar	CFTG
>A>	AB +		60MG;120MG	N20786	001	Dec 24, 1997	Mar	CFTG
>A>		FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL						
>A>	AB	BARR	60MG;120MG	N76236	001	Apr 14, 2005	Mar	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

		FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>A>	AP	APOTEX	200MG/100ML	N76888	001	Mar 25, 2005	Mar	NEWA
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>	AP	APOTEX	200MG/100ML	N76889	001	Mar 25, 2005	Mar	NEWA

FLUOCINONIDE

CREAM; TOPICAL

		VANOS						
	+	MEDICIS	0.1%	N21758	001	Feb 11, 2005	Feb	NEWA

SOLUTION; TOPICAL

		FLUOCINONIDE						
>D>	AT	COPLEY PHARM	0.05%	N72522	001	Sep 28, 1990	Mar	CAHN
>A>	AT	TEVA PHARMS	0.05%	N72522	001	Sep 28, 1990	Mar	CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		FLUPHENAZINE HCL						
>D>	AA	COPLEY PHARM	5MG/ML	N73058	001	Aug 30, 1991	Mar	CAHN
>A>	AA	TEVA PHARMS	5MG/ML	N73058	001	Aug 30, 1991	Mar	CAHN

ELIXIR; ORAL

		FLUPHENAZINE HCL						
>D>	AA	COPLEY PHARM	2.5MG/5ML	N81310	001	Apr 29, 1993	Mar	CAHN
>A>	AA	TEVA PHARMS	2.5MG/5ML	N81310	001	Apr 29, 1993	Mar	CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

		FLOVENT						
	+	GLAXOSMITHKLINE	0.044MG/INH	N20548	001	Mar 27, 1996	Jan	CRLD
	+		0.11MG/INH	N20548	002	Mar 27, 1996	Jan	CRLD
		FLOVENT HFA						
	+	GLAXOSMITHKLINE	0.044MG/INH	N21433	003	May 14, 2004	Jan	CRLD
	+		0.11MG/INH	N21433	002	May 14, 2004	Jan	CRLD
>A>		LOTION; TOPICAL						
>A>		CUTIVATE						
>A>	+	GLAXOSMITHKLINE	0.05%	N21152	001	Mar 31, 2005	Mar	NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

		FOLLISTIM AQ						
	+	ORGANON USA INC	150 IU/0.18ML	N21211	003	Feb 11, 2004	Feb	NEWA
	+		300 IU/0.36ML	N21211	001	Mar 23, 2004	Jan	CPOT
	+		600 IU/0.72ML	N21211	002	Mar 23, 2004	Jan	CPOT
	+		900 IU/1.08ML	N21211	004	Feb 11, 2005	Feb	NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

		VITRAVENE PRESERVATIVE FREE						
	@	NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Feb	DISC

FOSINOPRIL SODIUM

TABLET; ORAL

		FOSINOPRIL SODIUM						
>A>	AB	INVAGEN PHARMS	10MG	N77222	001	Apr 20, 2005	Mar	NEWA
>A>	AB		20MG	N77222	002	Apr 20, 2005	Mar	NEWA
>A>	AB		40MG	N77222	003	Apr 20, 2005	Mar	NEWA

FUROSEMIDE

INJECTABLE; INJECTION

		FUROSEMIDE						
	AP +	LUITPOLD	10MG/ML	N18579	001	Nov 30, 1983	Feb	CRLD
		LASIX						
	@	AVENTIS PHARMS	10MG/ML	N16363	001		Feb	DISC

GABAPENTIN

CAPSULE; ORAL

		GABAPENTIN						
>A>	AB	APOTEX	100MG	N75360	001	Apr 06, 2005	Mar	NEWA
>A>	AB		300MG	N75360	002	Apr 06, 2005	Mar	NEWA
>A>	AB		400MG	N75360	003	Apr 06, 2005	Mar	NEWA
>A>	AB	EON	100MG	N75539	001	Apr 06, 2005	Mar	NEWA
>A>	AB		300MG	N75539	002	Apr 06, 2005	Mar	NEWA
>A>	AB		400MG	N75539	003	Apr 06, 2005	Mar	NEWA
>A>	AB	IVAX PHARMS	100MG	N75477	001	Mar 23, 2005	Mar	NEWA
>A>	AB		300MG	N75477	002	Mar 23, 2005	Mar	NEWA
>A>	AB		400MG	N75477	003	Mar 23, 2005	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

REMINYL

+	JOHNSON AND JOHNSON	EQ 8MG BASE		N21615	001	Dec 22, 2004	Jan	CRLD
		EQ 24MG BASE		N21615	003	Dec 22, 2004	Jan	CRLD

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

>D>	+ BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)		N21062	001	Dec 17, 1999	Mar	CPOT
>D>	+	EQ 2MG /ML(400MG/200ML)		N21062	002	Dec 17, 1999	Mar	CPOT
>D>	+	EQ 10MG /ML(400MG)		N21062	004	Dec 17, 1999	Mar	CPOT
>A>	+	400MG/40ML(10MG/ML)		N21062	004	Dec 17, 1999	Mar	CPOT

TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	+ BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)		N21062	001	Dec 17, 1999	Mar	CPOT
>A>	+	400MG/200ML(2MG/ML)		N21062	002	Dec 17, 1999	Mar	CPOT

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HCL

AB	TEVA	1.25MG;250MG		N76821	001	Jan 27, 2005	Jan	NEWA
AB		2.5MG;500MG		N76821	002	Jan 27, 2005	Jan	NEWA
AB		5MG;500MG		N76821	003	Jan 27, 2005	Jan	NEWA

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

	@ WATSON LABS (UTAH)	2,000 UNITS/VIAL		N17016	009	Dec 27, 1984	Feb	CAHN
	@	2,000 UNITS/VIAL		N17016	011	Feb 16, 1990	Feb	CAHN
	@	5,000 UNITS/VIAL		N17016	006		Feb	CAHN
AP	+	10,000 UNITS/VIAL		N17016	007		Feb	CAHN
	@	15,000 UNITS/VIAL		N17016	010	Feb 15, 1985	Feb	CAHN
	@	20,000 UNITS/VIAL		N17016	004		Feb	CAHN

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ J AND J	125MG/5ML		N62483	001	Jan 26, 1984	Feb	CFTG

GRISEOFULVIN

AB	STIEFEL	125MG/5ML		N65200	001	Mar 02, 2005	Feb	NEWA

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

>D>	AB	COPLEY PHARM	EQ 4MG BASE		N74267	001	Jun 01, 1994	Mar	CAHN
>D>	AB		EQ 8MG BASE		N74267	002	Jun 01, 1994	Mar	CAHN
>A>	AB	TEVA PHARMS	EQ 4MG BASE		N74267	001	Jun 01, 1994	Mar	CAHN
>A>	AB		EQ 8MG BASE		N74267	002	Jun 01, 1994	Mar	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

>D>	AA	+ COPLEY PHARM	EQ 2MG BASE/ML		N71617	001	Dec 01, 1988	Mar	CAHN
>A>	AA	+ TEVA PHARMS	EQ 2MG BASE/ML		N71617	001	Dec 01, 1988	Mar	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

	AA		IVAX PHARMS	1.5MG/5ML;5MG/5ML	N40285	001	Jul 19, 1999	Jan	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL

		@	ABC HOLDING	10MG	N88846	001	Feb 26, 1985	Feb	DISC
		@		25MG	N88847	001	Feb 26, 1985	Feb	DISC
		@		50MG	N88848	001	Feb 26, 1985	Feb	DISC
		@		100MG	N88849	001	Feb 26, 1985	Feb	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

		@	ABC HOLDING	25MG	N85683	001		Feb	DISC
		@		50MG	N83965	001		Feb	DISC
		@		50MG	N85672	001		Feb	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

>D>		+	SANOFI SYNTHELABO	12.5MG;300MG	N20758	003	Aug 31, 1998	Mar	CRLD
>A>				12.5MG;300MG	N20758	003	Aug 31, 1998	Mar	CRLD
>A>		+		25MG;300MG	N20758	004	Mar 15, 2005	Mar	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
>A> QUINAPRIL HCL AND HYDROCHLOROTHIAZIDE

>A>	AB		MYLAN	12.5MG;EQ 10MG BASE	N77093	001	Mar 28, 2005	Mar	NEWA
>A>	AB			12.5MG;EQ 20MG BASE	N77093	002	Mar 28, 2005	Mar	NEWA
>A>	AB			25MG;EQ 20MG BASE	N77093	003	Mar 28, 2005	Mar	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

>D>		+	NOVARTIS	12.5MG;160MG	N20818	002	Mar 06, 1998	Mar	CRLD
>A>				12.5MG;160MG	N20818	002	Mar 06, 1998	Mar	CRLD
>D>				25MG;160MG	N20818	003	Jan 17, 2002	Mar	CRLD
>A>		+		25MG;160MG	N20818	003	Jan 17, 2002	Mar	CRLD

HYDROCORTISONE

ENEMA; RECTAL
HYDROCORTISONE

>D>	AB		COPLEY PHARM	100MG/60ML	N74171	001	May 27, 1994	Mar	CAHN
>A>	AB		TEVA PHARMS	100MG/60ML	N74171	001	May 27, 1994	Mar	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

>D>	AB		COPLEY PHARM	0.2%	N74489	001	Aug 12, 1998	Mar	CAHN
>A>	AB		TEVA PHARMS	0.2%	N74489	001	Aug 12, 1998	Mar	CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

			PURDUE PHARMA LP	16MG	N21044	002	Sep 24, 2004	Feb	CRLD
		+		32MG	N21044	004	Sep 24, 2004	Feb	CRLD

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

>D>	AB		COPLEY PHARM	200MG	N40081	001	Sep 30, 1994	Mar	CAHN
>A>	AB		TEVA PHARMS	200MG	N40081	001	Sep 30, 1994	Mar	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

>D>			@ STERIS	125MG/ML	N17439	001		Mar	CAHN
>D>			@	250MG/ML	N17439	002		Mar	CAHN
>A>			@ WATSON LABS	125MG/ML	N17439	001		Mar	CAHN
>A>			@	250MG/ML	N17439	002		Mar	CAHN

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

		+	ROCHE	EQ 2.5MG BASE	N21455	001	May 16, 2003	Feb	CMFD
>A>				EQ 150MG BASE	N21455	002	Mar 24, 2005	Mar	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

			@ TEVA	10MG	N83729	001		Feb	DISC
			@	25MG	N83729	004		Feb	DISC
			@	50MG	N83729	003		Feb	DISC

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

	BP	+	WATSON LABS (UTAH)	EQ 50MG IRON/ML	N17441	001		Feb	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

>D>		+	LUITPOLD	EQ 20MG BASE/ML	N21135	001	Nov 06, 2000	Mar	CPOT
>A>		+		EQ 100MG BASE/5ML(EQ 20MG BASE/ML)	N21135	001	Nov 06, 2000	Mar	CPOT
>A>				EQ 50MG BASE/2.5ML(EQ 20MG BASE/ML)	N21135	002	Mar 20, 2005	Mar	NEWA
>A>				EQ 75MG BASE/3.75ML(EQ 20MG BASE/ML)	N21135	003	Mar 29, 2005	Mar	NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

>D>		+	RELIANT PHARMS	5MG	N20336	001	Jun 01, 1994	Mar	CRLD
>A>				5MG	N20336	001	Jun 01, 1994	Mar	CRLD

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
@ APOTHECON EQ 500MG BASE N62726 001 Mar 06, 1987 Feb DISC

KETOCONAZOLE

SHAMPOO; TOPICAL
KETOCONAZOLE
>A> AB QLT USA 2% N76942 001 Apr 11, 2005 Mar NEWA

LACTULOSE

SOLUTION; ORAL
EVALOSE
>D> AA COPLEY PHARM 10GM/15ML N73497 001 May 28, 1993 Mar CAHN
>A> AA TEVA PHARMS 10GM/15ML N73497 001 May 28, 1993 Mar CAHN

SOLUTION; ORAL, RECTAL
HEPTALAC
>D> AA COPLEY PHARM 10GM/15ML N73504 001 May 28, 1993 Mar CAHN
>A> AA TEVA PHARMS 10GM/15ML N73504 001 May 28, 1993 Mar CAHN

>D> LEPIRUDIN

>D> INJECTABLE; INJECTION
>D> REFLUDAN
>D> + BERLEX 50MG/VIAL N20807 001 Mar 06, 1998 Mar CAIN

>A> LEPIRUDIN RECOMBINANT

>A> INJECTABLE; INJECTION
>A> REFLUDAN
>A> + BERLEX 50MG/VIAL N20807 001 Mar 06, 1998 Mar CAIN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS
ELIGARD
+ QLT USA 22.5MG/VIAL N21379 001 Jul 24, 2002 Jan CAHN

LEVALBUTEROL TARTRATE

>A> AEROSOL, METERED; INHALATION
>A> XOPENEX HFA
>A> + SEPRACOR EQ 0.045MG BASE/INH N21730 001 Mar 11, 2005 Mar NEWA

LEVOFLOXACIN

TABLET; ORAL
LEVAQUIN
>D> AB ORTHO MCNEIL PHARM 250MG N20634 001 Dec 20, 1996 Mar CTEC
>A> 250MG N20634 001 Dec 20, 1996 Mar CTEC
>D> AB 500MG N20634 002 Dec 20, 1996 Mar CTEC
>A> 500MG N20634 002 Dec 20, 1996 Mar CTEC
AB + 750MG N20634 003 Sep 08, 2000 Jan CFTG
LEVOFLOXACIN
AB TEVA 750MG N76361 003 Jan 26, 2005 Jan NEWA

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
LIDOCAINE HCL
>D> AT COPLEY PHARM 2% N81318 001 Apr 29, 1993 Mar CAHN

JELLY; TOPICAL
LIDOCAINE HCL

>A>	AT	TEVA PHARMS	2%	N81318	001	Apr 29, 1993	Mar	CAHN

LORAZEPAM

SOLUTION; ORAL
LORAZEPAM

		ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Jan	CMFD

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION
TESLASCAN

		@ GE HEALTHCARE	37.9MG/ML	N20652	001	Nov 26, 1997	Jan	DISC

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
MEBENDAZOLE

>D>	AB	COPLEY PHARM	100MG	N73580	001	Jan 04, 1995	Mar	CAHN
>A>	AB	TEVA PHARMS	100MG	N73580	001	Jan 04, 1995	Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

		@ ABC HOLDING	12.5MG	N85253	001		Feb	DISC
		@	25MG	N85252	001		Feb	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

>D>	AB	COPLEY PHARM	40MG/ML	N75681	001	May 05, 2003	Mar	CAHN
>A>	AB	TEVA PHARMS	40MG/ML	N75681	001	May 05, 2003	Mar	CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

		+ BARRIER	2%;0.01%	N20922	001	Dec 10, 1999	Feb	CAHN

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

>D>		@ COPLEY PHARM	10MG/5ML	N73034	001	Aug 30, 1991	Mar	CAHN
>A>		@ TEVA PHARMS	10MG/5ML	N73034	001	Aug 30, 1991	Mar	CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HCL

>A>	AB	ANDRX PHARMS	750MG	N76869	001	Apr 12, 2005	Mar	NEWA
>A>	AB	PUREPAC PHARM	750MG	N76878	001	Apr 13, 2005	Mar	NEWA
>A>	AB	TEVA	750MG	N76864	001	Apr 12, 2005	Mar	NEWA
>A>	AB	ZYDUS PHARMS USA	500MG	N77060	001	Apr 20, 2005	Mar	NEWA

TABLET; ORAL
METFORMIN HCL

>A>	AB	ZYDUS PHARMS USA	500MG	N77064	001	Apr 18, 2005	Mar	NEWA
>A>	AB		850MG	N77064	002	Apr 18, 2005	Mar	NEWA
>A>	AB		1GM	N77064	003	Apr 18, 2005	Mar	NEWA

METHAZOLAMIDE

TABLET; ORAL

			METHAZOLAMIDE						
>D>	AB		COPLEY PHARM	25MG	N40001	001	Jun 30, 1993	Mar	CAHN
>D>	AB			50MG	N40001	002	Jun 30, 1993	Mar	CAHN
>A>	AB		TEVA PHARMS	25MG	N40001	001	Jun 30, 1993	Mar	CAHN
>A>	AB			50MG	N40001	002	Jun 30, 1993	Mar	CAHN

METHIMAZOLE

TABLET; ORAL

			METHIMAZOLE						
	AB		CEDAR PHARMS	5MG	N40547	001	Feb 18, 2005	Jan	NEWA
	AB			10MG	N40547	002	Feb 18, 2005	Jan	NEWA
	AB			20MG	N40547	004	Feb 18, 2005	Jan	NEWA
	AB	+	GENPHARM	20MG	N40350	003	Jun 07, 2001	Jan	CFTG

METHYLDOPA

TABLET; ORAL

			ALDOMET						
			@ MERCK	500MG	N13400	002		Jan	DISC
			METHYLDOPA						
	AB	+	MYLAN	500MG	N70076	001	Apr 18, 1985	Jan	CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

			ALDOMET						
			@ MERCK	50MG/ML	N13401	001		Jan	DISC
			METHYLDOPATE HCL						
	AP	+	LUITPOLD	50MG/ML	N71279	001	Oct 02, 1987	Jan	CRLD

METHYLERGONOVINE MALEATE

TABLET; ORAL

			METHERGINE						
		+	NOVARTIS	0.2MG	N06035	003		Jan	CRLD

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

			DEPO-MEDROL						
	AB	+	PHARMACIA AND UPJOHN	40MG/ML	N11757	001		Feb	CFTG
	AB	+		80MG/ML	N11757	004		Feb	CFTG
			METHYLPREDNISOLONE ACETATE						
	AB		SICOR PHARMS	40MG/ML	N40557	001	Feb 23, 2005	Feb	NEWA
	AB			80MG/ML	N40557	002	Feb 23, 2005	Feb	NEWA

METOLAZONE

TABLET; ORAL

			ZAROXOLYN						
>D>	AB		CELLTECH PHARMS	2.5MG	N17386	001		Mar	CAHN
>D>	AB	+		5MG	N17386	002		Mar	CAHN
>D>	AB	+		10MG	N17386	003		Mar	CAHN
>A>	AB		UCB	2.5MG	N17386	001		Mar	CAHN
>A>	AB	+		5MG	N17386	002		Mar	CAHN
>A>	AB	+		10MG	N17386	003		Mar	CAHN

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

>D>	AB	COPLEY PHARM	50MG	N74333	001	Jan 27, 1994	Mar	CAHN
>D>	AB		100MG	N74333	002	Jan 27, 1994	Mar	CAHN
>A>	AB	TEVA PHARMS	50MG	N74333	001	Jan 27, 1994	Mar	CAHN
>A>	AB		100MG	N74333	002	Jan 27, 1994	Mar	CAHN

>A> MICAFUNGIN SODIUM

>A> INJECTABLE; IV (INFUSION)
>A> MYCAMINE

>A>	+	ASTELLAS	50MG/VIAL	N21506	002	Mar 16, 2005	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

>D>		@ HOSPIRA	EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	Mar	CMFD
>A>	AP		EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	Mar	CMFD
>D>		@	EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CMFD
>A>	AP		EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CMFD
	AP	INTL MEDICATED	EQ 1MG BASE/ML	N76144	001	Jan 26, 2005	Jan	NEWA
	AP		EQ 5MG BASE/ML	N76144	002	Jan 26, 2005	Jan	NEWA

MOMETASONE FUROATE

CREAM; TOPICAL
ELOCON

	AB	+ SCHERING	0.1%	N19625	001	May 06, 1987	Jan	CFTG

MOMETASONE FUROATE

>A>	AB	ALTANA	0.1%	N76171	001	Apr 08, 2005	Mar	NEWA
	AB	TARO	0.1%	N76679	001	Dec 21, 2004	Jan	NEWA

LOTION; TOPICAL
ELOCON

>D>		+ SCHERING	0.1%	N19796	001	Mar 30, 1989	Mar	CFTG
>A>	AB	+	0.1%	N19796	001	Mar 30, 1989	Mar	CFTG

>A> MOMETASONE FUROATE

>A>	AB	AGIS INDS	0.1%	N77180	001	Apr 06, 2005	Mar	NEWA

OINTMENT; TOPICAL
MOMETASONE FUROATE

>A>	AB	ALTANA	0.1%	N77061	001	Mar 28, 2005	Mar	NEWA

>A> POWDER; INHALATION
>A> ASMANEX TWISTHALER

>A>		+ SCHERING	0.22MG/INH	N21067	001	Mar 30, 2005	Mar	NEWA

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

>D>		+ SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Mar	CAHN
>A>		+ SHIRE	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

>D>	BX	+ LIGAND	30MG	N21260	001	Mar 20, 2002	Mar	CRLD
>A>	BX		30MG	N21260	001	Mar 20, 2002	Mar	CRLD
>D>	BX	+	60MG	N21260	002	Mar 20, 2002	Mar	CRLD

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

>A>	BX		LIGAND	60MG	N21260	002	Mar 20, 2002	Mar	CRLD
>D>		+		90MG	N21260	003	Mar 20, 2002	Mar	CRLD
>A>				90MG	N21260	003	Mar 20, 2002	Mar	CRLD

KADIAN

>D>		+	ALPHARMA US PHARMS	20MG	N20616	001	Jul 03, 1996	Mar	CRLD
>A>				20MG	N20616	001	Jul 03, 1996	Mar	CRLD
>D>	BX	+		30MG	N20616	004	Mar 09, 2001	Mar	CRLD
>A>	BX			30MG	N20616	004	Mar 09, 2001	Mar	CRLD
>D>		+		50MG	N20616	002	Jul 03, 1996	Mar	CRLD
>A>				50MG	N20616	002	Jul 03, 1996	Mar	CRLD
>D>	BX	+		60MG	N20616	005	Mar 09, 2001	Mar	CRLD
>A>	BX			60MG	N20616	005	Mar 09, 2001	Mar	CRLD

NADOLOL

TABLET; ORAL

NADOLOL

>D>	AB		COPLEY PHARM	80MG	N74368	001	Aug 31, 1994	Mar	CAHN
>D>	AB			120MG	N74368	002	Aug 31, 1994	Mar	CAHN
>D>	AB			160MG	N74368	003	Aug 31, 1994	Mar	CAHN
>A>	AB		TEVA PHARMS	80MG	N74368	001	Aug 31, 1994	Mar	CAHN
>A>	AB			120MG	N74368	002	Aug 31, 1994	Mar	CAHN
>A>	AB			160MG	N74368	003	Aug 31, 1994	Mar	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

>D>			@ HOSPIRA	0.4MG/ML	N70172	001	Sep 24, 1986	Mar	CMFD
>A>	AP			0.4MG/ML	N70172	001	Sep 24, 1986	Mar	CMFD

NAPROXEN

TABLET; ORAL

NAPROXEN

>D>	AB		COPLEY PHARM	250MG	N74207	001	Dec 21, 1993	Mar	CAHN
>D>	AB			375MG	N74207	002	Dec 21, 1993	Mar	CAHN
>D>	AB			500MG	N74207	003	Dec 21, 1993	Mar	CAHN
>A>	AB		TEVA PHARMS	250MG	N74207	001	Dec 21, 1993	Mar	CAHN
>A>	AB			375MG	N74207	002	Dec 21, 1993	Mar	CAHN
>A>	AB			500MG	N74207	003	Dec 21, 1993	Mar	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>D>	AB		COPLEY PHARM	EQ 250MG BASE	N74289	001	Jan 27, 1994	Mar	CAHN
>D>	AB			EQ 500MG BASE	N74289	002	Jan 27, 1994	Mar	CAHN
>A>	AB		TEVA PHARMS	EQ 250MG BASE	N74289	001	Jan 27, 1994	Mar	CAHN
>A>	AB			EQ 500MG BASE	N74289	002	Jan 27, 1994	Mar	CAHN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

>A> NIACIN

>A>	AB		BARR	1GM	N76250	001	Apr 14, 2005	Mar	NEWA

NIASPAN

>D>		+	KOS	1GM	N20381	004	Jul 28, 1997	Mar	CFTG
>A>	AB	+		1GM	N20381	004	Jul 28, 1997	Mar	CFTG

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

>A>		+	ESP PHARMA	2.5MG/ML	N19734	001	Jan 30, 1992	Mar	CAHN
>D>		+	ROCHE PALO	2.5MG/ML	N19734	001	Jan 30, 1992	Mar	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A>	AB		EON	75MG;25MG	N77066	001	Apr 05, 2005	Mar	NEWA
>A>	AB		RANBAXY	75MG;25MG	N76951	001	Mar 30, 2005	Mar	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

>A> OCTREOTIDE ACETATE

>A>	AP		BEDFORD	EQ 0.2MG BASE/ML	N76330	001	Apr 08, 2005	Mar	NEWA
>A>	AP			EQ 1MG BASE/ML	N76330	002	Apr 08, 2005	Mar	NEWA

>A> OCTREOTIDE ACETATE (PRESERVATIVE FREE)

>A>	AP		BEDFORD	EQ 0.05MG BASE/ML	N76313	001	Mar 28, 2005	Mar	NEWA
>A>	AP			EQ 0.1MG BASE/ML	N76313	003	Mar 28, 2005	Mar	NEWA
>A>	AP			EQ 0.5MG BASE/ML	N76313	002	Mar 28, 2005	Mar	NEWA

SANDOSTATIN

>D>		+	NOVARTIS	EQ 0.05MG BASE/ML	N19667	001	Oct 21, 1988	Mar	CFTG
>A>	AP	+		EQ 0.05MG BASE/ML	N19667	001	Oct 21, 1988	Mar	CFTG
>D>		+		EQ 0.1MG BASE/ML	N19667	002	Oct 21, 1988	Mar	CFTG
>A>	AP	+		EQ 0.1MG BASE/ML	N19667	002	Oct 21, 1988	Mar	CFTG
>D>		+		EQ 0.2MG BASE/ML	N19667	004	Jun 12, 1991	Mar	CFTG
>A>	AP	+		EQ 0.2MG BASE/ML	N19667	004	Jun 12, 1991	Mar	CFTG
>D>		+		EQ 0.5MG BASE/ML	N19667	003	Oct 21, 1988	Mar	CFTG
>A>	AP	+		EQ 0.5MG BASE/ML	N19667	003	Oct 21, 1988	Mar	CFTG
>D>		+		EQ 1MG BASE/ML	N19667	005	Jun 12, 1991	Mar	CFTG
>A>	AP	+		EQ 1MG BASE/ML	N19667	005	Jun 12, 1991	Mar	CFTG

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

>D>		+	CELLTECH PHARMS	250MG	N19715	001	Jul 31, 1990	Mar	CAHN
>A>		+	UCB	250MG	N19715	001	Jul 31, 1990	Mar	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

>D>	AB	+	ASTRAZENECA	40MG	N19810	002	Jan 15, 1998	Mar	CTEC
>A>				40MG	N19810	002	Jan 15, 1998	Mar	CTEC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

>D>			SANOFI	50MG/VIAL	N21492	001	Aug 09, 2002	Mar	CRLD
>A>		+		50MG/VIAL	N21492	001	Aug 09, 2002	Mar	CRLD
		+	SANOFI SYNTHELABO	50MG/10ML (5MG/ML)	N21759	001	Jan 31, 2005	Jan	NEWA
		+		100MG/20ML (5MG/ML)	N21759	002	Jan 31, 2005	Jan	NEWA

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

		ABRAXANE							
	+	AM BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Jan		NEWA

PEMOLINE

TABLET, CHEWABLE; ORAL

		PEMOLINE							
>D>	AB	COPLEY PHARM	37.5MG	N75555	001	Feb 18, 2000	Mar		CAHN
>A>	AB	TEVA PHARMS	37.5MG	N75555	001	Feb 18, 2000	Mar		CAHN

TABLET; ORAL

		PEMOLINE							
>D>	AB	COPLEY PHARM	18.75MG	N75030	003	Feb 22, 2000	Mar		CAHN
>D>	AB		37.5MG	N75030	001	Jan 29, 1999	Mar		CAHN
>D>	AB		75MG	N75030	002	Jan 29, 1999	Mar		CAHN
>A>	AB	TEVA PHARMS	18.75MG	N75030	003	Feb 22, 2000	Mar		CAHN
>A>	AB		37.5MG	N75030	001	Jan 29, 1999	Mar		CAHN
>A>	AB		75MG	N75030	002	Jan 29, 1999	Mar		CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL

		SODIUM PENTOBARBITAL							
	@	VALEANT PHARM INTL	100MG	N83264	001		Jan		DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

		BONTRIL PDM							
AA	+	VALEANT	35MG	N85272	001		Feb		CRLD
		CAM-METRAZINE							
	@	ABC HOLDING	35MG	N83922	001		Feb		DISC
	@		35MG	N85318	001		Feb		DISC
	@		35MG	N85320	001		Feb		DISC
	@		35MG	N85321	001		Feb		DISC
	@		35MG	N85511	001		Feb		DISC
	@	CAMALL	35MG	N85756	001		Feb		DISC
		PHENDIMETRAZINE TARTRATE							
	@	ABC HOLDING	35MG	N85761	001		Feb		DISC
	@		35MG	N85941	001	Jun 27, 1983	Feb		DISC
	@	EON	35MG	N85830	001		Feb		DISC
		X-TROZINE							
	@	SHIRE RICHWOOD	35MG	N86553	001		Feb		DISC
	@		35MG	N86554	001		Feb		DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

		ONA-MAST							
	@	MAST MM	30MG	N86511	001		Feb		DISC
	@		30MG	N86516	001		Feb		DISC
		PHENTERMINE HCL							
	@	ABC HOLDING	18.75MG	N88576	001	May 23, 1984	Feb		DISC
	@		30MG	N85417	001		Feb		DISC
	@		30MG	N86732	002		Feb		DISC
	@		30MG	N87215	001		Feb		DISC
	@		37.5MG	N87915	001	Dec 22, 1983	Feb		DISC
	@		37.5MG	N87918	001	Dec 22, 1983	Feb		DISC

CAPSULE; ORAL
PHENTERMINE HCL

		@ ABC HOLDING	37.5MG	N87930	001	Oct 14, 1983	Feb	DISC
		@	37.5MG	N88610	001	Jun 04, 1984	Feb	DISC
		@	37.5MG	N88611	001	Jun 04, 1984	Feb	DISC
		@	37.5MG	N88625	001	Aug 23, 1984	Feb	DISC
		@ CAMALL	15MG	N86735	001		Feb	DISC
		@	30MG	N87226	001		Feb	DISC

TABLET; ORAL
ONA MAST

		@ MAST MM	8MG	N86260	001		Feb	DISC

PHENTERMINE HCL

		@ ABC HOLDING	8MG	N83923	001		Feb	DISC
		@	8MG	N85319	001		Feb	DISC
		@	37.5MG	N87805	001	Dec 06, 1982	Feb	DISC
		@	37.5MG	N88596	001	Apr 04, 1984	Feb	DISC
>A>	AA	LANNETT	37.5MG	N40555	001	Apr 15, 2005	Mar	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN

>D>		CELLTECH PHARMS	EQ 15MG BASE	N11613	004		Mar	CAHN
>D>		+	EQ 30MG BASE	N11613	002		Mar	CAHN
>A>		UCB	EQ 15MG BASE	N11613	004		Mar	CAHN
>A>		+	EQ 30MG BASE	N11613	002		Mar	CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN

>D>		+ ELKINS SINN	50MG/ML	N84307	001		Mar	CTEC
>A>	AP	+	50MG/ML	N84307	001		Mar	CTEC

PHENYTOIN SODIUM

>D>		@ HOSPIRA	50MG/ML	N89521	001	Mar 17, 1987	Mar	CMFD
>A>	AP		50MG/ML	N89521	001	Mar 17, 1987	Mar	CMFD
>D>		@	50MG/ML	N89744	001	Dec 18, 1987	Mar	CMFD
>A>	AP		50MG/ML	N89744	001	Dec 18, 1987	Mar	CMFD

PIROXICAM

CAPSULE; ORAL
PIROXICAM

>D>	AB	COPLEY PHARM	10MG	N74103	001	Aug 28, 1992	Mar	CAHN
>D>	AB		20MG	N74103	002	Aug 28, 1992	Mar	CAHN
>A>	AB	TEVA PHARMS	10MG	N74103	001	Aug 28, 1992	Mar	CAHN
>A>	AB		20MG	N74103	002	Aug 28, 1992	Mar	CAHN

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

>D>		@ HOSPIRA	14.9MG/ML	N20161	005	Nov 30, 1992	Mar	CMFD
>A>	AP		14.9MG/ML	N20161	005	Nov 30, 1992	Mar	CMFD
>D>		@	745MG/100ML	N20161	001	Nov 30, 1992	Mar	CMFD
>A>	AP		745MG/100ML	N20161	001	Nov 30, 1992	Mar	CMFD

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

>D>		@ HOSPIRA	1.49GM/100ML	N20161	002	Nov 30, 1992	Mar	CMFD
>A>	AP		1.49GM/100ML	N20161	002	Nov 30, 1992	Mar	CMFD

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

UROCIT-K

		MISSION PHARMA	5MEQ	N19071	001	Aug 30, 1985	Jan	CTNA
	+		10MEQ	N19071	002	Aug 31, 1992	Jan	CTNA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

>A>	+	AMYLIN	EQ 3MG BASE/5ML (EQ 0.6MG BASE/ML)	N21332	001	Mar 16, 2005	Mar	NEWA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

>D>	AA	COPLEY PHARM	15MG/5ML	N40322	001	Jan 19, 2000	Mar	CAHN
	AA	IVAX PHARMS	15MG/5ML	N40287	001	May 28, 1999	Jan	CAHN
>A>	AA	TEVA PHARMS	15MG/5ML	N40322	001	Jan 19, 2000	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

>D>	AA	+ CELLTECH PHARMS	EQ 5MG BASE/5ML	N19157	001	May 28, 1986	Mar	CAHN
>A>	AA	+ UCB	EQ 5MG BASE/5ML	N19157	001	May 28, 1986	Mar	CAHN

PRIMIDONE

TABLET; ORAL

PRIMIDONE

	AB	VINTAGE PHARMS	50MG	N40586	001	Feb 24, 2005	Feb	NEWA
	AB		250MG	N40586	002	Feb 24, 2005	Feb	NEWA

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

>D>	AB	COPLEY PHARM	EQ 5MG BASE	N40120	001	Jul 11, 1996	Mar	CAHN
>D>	AB		EQ 10MG BASE	N40120	002	Jul 11, 1996	Mar	CAHN
>A>	AB	TEVA PHARMS	EQ 5MG BASE	N40120	001	Jul 11, 1996	Mar	CAHN
>A>	AB		EQ 10MG BASE	N40120	002	Jul 11, 1996	Mar	CAHN

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

	AO	+ WATSON LABS (UTAH)	50MG/ML	N17362	002		Feb	CAHN

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HCL

		ABLE	12.5MG	N40558	001	Jul 01, 2004	Jan	CTEC

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

>A>	AB	BEDFORD	10MG/ML	N74848	001	Apr 19, 2005	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HCL

AB	EON	EQ 5MG BASE	N76803	001	Mar 02, 2005	Feb	NEWA
AB		EQ 10MG BASE	N76803	002	Mar 02, 2005	Feb	NEWA
AB		EQ 20MG BASE	N76803	003	Mar 02, 2005	Feb	NEWA
AB		EQ 40MG BASE	N76803	004	Mar 02, 2005	Feb	NEWA
AB	PAR PHARM	EQ 5MG BASE	N76036	001	Jan 28, 2005	Jan	NEWA
AB		EQ 10MG BASE	N76036	002	Jan 28, 2005	Jan	NEWA
AB		EQ 20MG BASE	N76036	003	Jan 28, 2005	Jan	NEWA
AB		EQ 40MG BASE	N76036	004	Jan 28, 2005	Jan	NEWA

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE SULFATE

>D>	+ COPLEY PHARM	300MG	N40045	001	Jun 30, 1994	Mar	CAHN
>A>	+ TEVA PHARMS	300MG	N40045	001	Jun 30, 1994	Mar	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
RANITIDINE HCL

AP	BEN VENUE	EQ 25MG BASE/ML	N74777	001	Mar 02, 2005	Feb	NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)
AMMONUL

	+ UCYCLYD	10%;10% (5GM/50ML;5GM/50ML)	N20645	001	Feb 17, 2005	Feb	NEWA

SODIUM CHLORIDE

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	@ HOSPIRA	450MG/100ML	N18380	001		Mar	CMFD
>A>	AT	450MG/100ML	N18380	001		Mar	CMFD

>D> SOMATREM

>D> INJECTABLE; INJECTION
>D> PROTROPIN

>D>	+ GENENTECH	5MG/VIAL	N19107	001	Oct 17, 1985	Mar	DISC
>A>	@	5MG/VIAL	N19107	001	Oct 17, 1985	Mar	DISC
>D>	+	10MG/VIAL	N19107	002	Oct 24, 1989	Mar	DISC
>A>	@	10MG/VIAL	N19107	002	Oct 24, 1989	Mar	DISC

SOMATROPIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
SEROSTIM LQ

	SERONO	6MG/0.05VIAL	N20604	005	Feb 11, 2005	Feb	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	INTERPHARM	400MG;80MG	N76899	001	Jan 27, 2005	Jan	NEWA
AB		800MG;160MG	N76899	002	Jan 27, 2005	Jan	NEWA

TACROLIMUS

CAPSULE; ORAL
PROGRAF

		+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708	001	Apr 08, 1994	Jan	CRLD

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

		@	PHARMACHEMIE	EQ 10MG BASE	N74539	001	Mar 31, 2003	Feb	DISC

TELITHROMYCIN

TABLET; ORAL
KETEK

			AVENTIS PHARMS	300MG	N21144	002	Feb 09, 2005	Feb	NEWA

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

>A>	AB		LANNETT	2.5MG	N77152	001	Mar 25, 2005	Mar	NEWA
>A>	AB			5MG	N77152	002	Mar 25, 2005	Mar	NEWA

TERCONAZOLE

CREAM; VAGINAL
TERCONAZOLE

	AB		ALTANA	0.4%	N76712	001	Feb 18, 2005	Jan	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

	AO		PADDOCK	200MG/ML	N40530	001	Jan 31, 2005	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
SUMYCIN

>D>			APOTHECON	250MG	N60429	001		Mar	DISC
>A>			@	250MG	N60429	001		Mar	DISC
>D>	AB	+		500MG	N60429	003		Mar	DISC
>A>			@	500MG	N60429	003		Mar	DISC

TETRACYCLINE HCL

>D>	AB		IVAX PHARMS	500MG	N60704	002		Mar	CRLD
>A>	AB	+		500MG	N60704	002		Mar	CRLD
			@ MAST MM	250MG	N62085	001		Feb	DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

>D>	AA	+	COPLEY PHARM	30MG/ML	N89602	001	Nov 09, 1987	Mar	CAHN
>D>	AA	+		100MG/ML	N89603	001	Nov 09, 1987	Mar	CAHN
>A>	AA	+	TEVA PHARMS	30MG/ML	N89602	001	Nov 09, 1987	Mar	CAHN
>A>	AA	+		100MG/ML	N89603	001	Nov 09, 1987	Mar	CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

>D>	AA		COPLEY PHARM	EQ 5MG BASE/ML	N71554	001	Oct 16, 1987	Mar	CAHN

CONCENTRATE; ORAL
THIOTHIXENE HCL

>A>	AA	TEVA PHARMS	EQ 5MG BASE/ML	N71554	001	Oct 16, 1987	Mar	CAHN

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON

	+	GTX INC	EQ 60MG BASE	N20497	001	May 29, 1997	Jan	CAHN

TORSEMIDE

TABLET; ORAL
TORSEMIDE

	AB	ROXANE	5MG	N76943	001	Mar 01, 2005	Feb	NEWA
	AB		10MG	N76943	002	Mar 01, 2005	Feb	NEWA
	AB		20MG	N76943	003	Mar 01, 2005	Feb	NEWA

TRETINOIN

SOLUTION; TOPICAL
TRETINOIN

>D>	AT	COPLEY PHARM	0.05%	N74873	001	Jun 19, 1998	Mar	CAHN
>A>	AT	TEVA PHARMS	0.05%	N74873	001	Jun 19, 1998	Mar	CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA

		@ SCHERING	4MG	N12265	002		Feb	DISC

TRICHLORMETHIAZIDE

		@ ABC HOLDING	4MG	N85568	001		Feb	DISC
		@ PAR PHARM	2MG	N87007	001		Feb	DISC
		@	4MG	N87005	001		Feb	DISC

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

		@ TARO PHARMS NORTH	EQ 25MG BASE/5ML	N74374	001	Jun 23, 1995	Jan	CAHN
	+		EQ 50MG BASE/5ML	N74973	001	Jan 24, 2000	Jan	CAHN

URSODIOL

CAPSULE; ORAL
URSODIOL

>D>	AB	COPLEY PHARM	300MG	N75592	001	May 25, 2000	Mar	CAHN
>A>	AB	TEVA PHARMS	300MG	N75592	001	May 25, 2000	Mar	CAHN

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

>D>	AA	COPLEY PHARM	250MG/5ML	N73178	001	Aug 25, 1992	Mar	CAHN
>A>	AA	TEVA PHARMS	250MG/5ML	N73178	001	Aug 25, 1992	Mar	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN PM

>D>	+	ELAN PHARM	100MG	N20943	001	Nov 25, 1998	Mar	CRLD
>A>			100MG	N20943	001	Nov 25, 1998	Mar	CRLD
>D>	+		200MG	N20943	002	Nov 25, 1998	Mar	CRLD
>A>			200MG	N20943	002	Nov 25, 1998	Mar	CRLD

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>A>	AP	AM PHARM	EQ 10MG BASE/ML	N76849	001	Apr 18, 2005	Mar	NEWA

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

>D>	@ BAYER	500MG	N21317	001	Oct 18, 2001	Mar	CMFD
>A>		500MG	N21317	001	Oct 18, 2001	Mar	CMFD

CLOTRIMAZOLE

TABLET; VAGINAL

GYNIX

>D>	COPLEY PHARM	100MG	N73249	001	Feb 13, 1998	Mar	CAHN
>A>	TEVA PHARMS	100MG	N73249	001	Feb 13, 1998	Mar	CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A>	PERRIGO	10MG	N75400	001	Mar 18, 2005	Mar	NEWA
	WOCKHARDT	10MG	N77146	001	Mar 07, 2005	Feb	NEWA

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

	@ SCHERING	1MG/ML	N20641	003	Nov 19, 2003	Jan	DISC

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 3

	TARO	4%	N76773	001	Mar 02, 2005	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2005

NO MARCH 2005 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2005 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021457 001	ALBUTEROL SULFATE;ALBUTEROL SULFATE HF	5695743	JUL 06, 2010	DP U491		
>ADD>			5766573	NOV 29, 2009	U356		
			5605674	FEB 25, 2014	DP		
			6352684	NOV 28, 2009	DP		
	021726 001	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021726 002	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021726 003	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021726 004	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021713 001	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
						I-437	SEP 29, 2007
						I-401	AUG 28, 2006
	021248 001	ARSENIC TRIOXIDE;TRISENOX	6855339	NOV 10, 2018	U617		
			6861076	NOV 10, 2018	U617		
>ADD>	021411 007	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
>ADD>			5658590*PED	JAN 11, 2015		PED	MAY 26, 2008
>ADD>	021411 008	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
>ADD>			5658590*PED	JAN 11, 2015		PED	MAY 26, 2008
>ADD>	021602 001	BORTEZOMIB;VELCADE				I-452	MAR 25, 2008
>ADD>	021664 001	BROMFENAC SODIUM;XIBROM				NP	MAR 24, 2008
	020838 001	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	020838 002	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	020838 003	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	020838 004	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	021710 001	CARBAMAZEPINE;EQUETRO	5326570	JUL 23, 2011	DP U627		
			5912013	JUN 15, 2016	DP		
	021710 002	CARBAMAZEPINE;EQUETRO	5326570	JUL 23, 2011	DP U627		
			5912013	JUN 15, 2016	DP		
	021710 003	CARBAMAZEPINE;EQUETRO	5326570	JUL 23, 2011	DP U627		
			5912013	JUN 15, 2016	DP		
>ADD>	021197 001	CETRORELIX;CETROTIDE	6863891	FEB 19, 2013	U426		
>ADD>	021197 002	CETRORELIX;CETROTIDE	6863891	FEB 19, 2013	U426		
	021673 001	CLOFARABINE;CLOLAR	5661136	AUG 26, 2014	U626		
			5384310	MAY 23, 2009	DS DP		
			4918179	JUN 14, 2005	DS		
>ADD>	020222 001	COLESTIPOL HYDROCHLORIDE;COLESTID	5490987	FEB 13, 2013	DP		
	021572 001	DAPTOMYCIN;CUBICIN	6852689	SEP 24, 2019	U282		
	021572 002	DAPTOMYCIN;CUBICIN	6852689	SEP 24, 2019	U282		
>ADD>	021513 001	DARIFENACIN HYDROBROMIDE;ENABLEX	6106864	AUG 21, 2016	DP U630		
>ADD>			5096890	MAR 13, 2010	DS DP U631		
>ADD>	021513 002	DARIFENACIN HYDROBROMIDE;ENABLEX	6106864	AUG 21, 2016	DP U630		
>ADD>			5096890	MAR 13, 2010	DS DP U631		
>ADD>	021271 001	DESIRUDIN RECOMBINANT;IPRIVASK				NCE	APR 04, 2008
	021605 001	DESLORATADINE;CLARINEX D 24 HOUR				NCE	DEC 21, 2006
						PED	JUN 21, 2007
>ADD>						NC	MAR 03, 2008
	076068 001	DEXRAZOXANE HYDROCHLORIDE;DEXRAZOXANE				PC	AUG 27, 2005
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6720004	DEC 18, 2018	DP		
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6720004	DEC 18, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021269 001	DOXAZOSIN MESYLATE;CARDURA XL				NDF	FEB 22, 2008
>ADD>	021269 002	DOXAZOSIN MESYLATE;CARDURA XL	4837111	MAR 21, 2008	DP	NDF	FEB 22, 2008
>ADD>	021504 001	EPINEPHRINE;LIDOSITE TOPICAL SYS	6862473	SEP 30, 2013	DP		
	021437 001	EPLERENONE;INSPRA	4559332	APR 09, 2005	DS DP U537		
	021437 002	EPLERENONE;INSPRA	4559332	APR 09, 2005	DS DP U537		
	021437 003	EPLERENONE;INSPRA	4559332	APR 09, 2005	DS DP U537		
	021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
			5652233	FEB 02, 2013		PED	MAY 21, 2007
			5952323	MAY 15, 2017			
			5478820*PED	AUG 02, 2013			
			5652233*PED	AUG 02, 2013			
			5952323*PED	NOV 15, 2017			
	076323 001	ESMOLOL HYDROCHLORIDE;ESMOLOL HCL				PC	MAY 01, 2005
>ADD>	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2006	DS DP U373		
>ADD>			4738974*PED	OCT 19, 2006	U635		
>ADD>			6875872	MAY 27, 2014	DS U373		
>ADD>			6875872*PED	NOV 27, 2014			
>ADD>	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2006	DS DP U373		
>ADD>			4738974*PED	OCT 19, 2006	U635		
>ADD>			6875872	MAY 27, 2014	DS U373		
>ADD>			6875872*PED	NOV 27, 2014			
>ADD>	021443 001	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284	NP	DEC 20, 2007
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021443 002	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284	NP	DEC 20, 2007
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021443 003	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284		
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021443 004	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284		
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021476 001	ESZOPICLONE;LUNESTA	6864257	AUG 30, 2012	U629		
			6444673	JAN 16, 2012	DS DP		
			6319926	JAN 16, 2012	U620		
>ADD>	021476 002	ESZOPICLONE;LUNESTA	6864257	AUG 30, 2012	U629		
			6444673	JAN 16, 2012	DS DP		
			6319926	JAN 16, 2012	U620		
>ADD>	021476 003	ESZOPICLONE;LUNESTA	6864257	AUG 30, 2012	U629		
			6444673	JAN 16, 2012	DS DP		
			6319926	JAN 16, 2012	U620		
	021712 001	FAMOTIDINE;FLUXID	6024981	APR 09, 2018	DP		
			6221392	APR 09, 2018	DP		
	021712 002	FAMOTIDINE;FLUXID	6024981	APR 09, 2018	DP		
			6221392	APR 09, 2018	DP		
	020747 001	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 002	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 003	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 004	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 005	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 006	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	019813 005	FENTANYL;DURAGESIC-12				NPP	MAY 20, 2006
						PED	NOV 20, 2006
	021758 001	FLUOCINONIDE;VANOS				NP	FEB 11, 2008
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	6536427	MAR 01, 2011	DP		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	6536427	MAR 01, 2011	DP		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	6536427	MAR 01, 2011	DP		
>ADD>	021152 001	FLUTICASONE PROPIONATE;CUTIVATE				NDF	MAR 31, 2008
>ADD>						PED	SEP 30, 2008
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	6358527	JUN 06, 2017	DP U322		
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	6358527	JUN 06, 2017	DP U322		
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	6358527	JUN 06, 2017	DP U322		
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
			5464826	NOV 07, 2012	U146	PED	NOV 19, 2007
			4808614*PED	NOV 15, 2010			
			5464826*PED	MAY 07, 2013			
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012	U146	I-428	MAY 19, 2007
			4808614	MAY 15, 2010	DS	PED	NOV 19, 2007
			4808614*PED	NOV 15, 2010			
			5464826*PED	MAY 07, 2013			
	020239 003	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	DS DP U89	I-369	AUG 16, 2005
	020239 004	GRANISETRON HYDROCHLORIDE;KYTRIL				I-369	AUG 16, 2005
>ADD>	021455 002	IBANDRONATE SODIUM;BONIVA				D-96	MAR 24, 2008
>ADD>						NS	MAR 24, 2008
>ADD>						NCE	MAY 16, 2008
	021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
	021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
	021588 001	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
	021588 002	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
>ADD>	076104 001	ITRACONAZOLE;ITRACONAZOLE				PC	AUG 08, 2005
	020726 001	LETROZOLE;FEMARA				I-446	OCT 29, 2007
	021731 001	LEUPROLIDE ACETATE;ELIGARD	RE37950	OCT 03, 2008	DP U621		
			4938763	OCT 03, 2008	DP U621		
			5278201	JAN 11, 2011	DP		
			5324519	JUN 28, 2011	DP		
			5599552	FEB 04, 2014	DP U621		
			5739176	OCT 03, 2008	DP U621		
			6395293	SEP 28, 2013	DP		
			6565874	OCT 28, 2018	DP U621		
			6626870	MAR 27, 2020	DP		
			6773714	OCT 28, 2018	U621		
>ADD>	021730 001	LEVALBUTEROL TARTRATE;XOPENEX HFA				NP	MAR 11, 2008
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
			5688792*PED	MAY 18, 2015		I-431	JUN 23, 2007
			6514529*PED	SEP 15, 2021		PED	JAN 22, 2007
			6559305*PED	JUL 29, 2021		PED	OCT 18, 2005
						PED	DEC 23, 2007
						PED	JUN 19, 2006
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
			5688792*PED	MAY 18, 2015		I-431	JUN 23, 2007
			6514529*PED	SEP 15, 2021		PED	JAN 22, 2007
			6559305*PED	JUL 29, 2021		PED	OCT 18, 2005
						PED	DEC 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
						PED	JUN 19, 2006
	021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			5688792*PED	MAY 18, 2015		I-402	JUL 22, 2006
			6559305*PED	JUL 29, 2021		I-431	JUN 23, 2007
						PED	JUN 19, 2006
						PED	JAN 22, 2007
						PED	OCT 18, 2005
						PED	DEC 23, 2007
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			5688792*PED	MAY 18, 2015		I-402	JUL 22, 2006
			6559305*PED	JUL 29, 2021		I-431	JUN 23, 2007
						PED	OCT 18, 2005
						PED	JAN 22, 2007
						PED	DEC 23, 2007
						PED	JUN 19, 2006
>ADD>	021316 001	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021316 002	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021316 003	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021316 004	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021583 001	MEDROXYPROGESTERONE ACETATE;DEPO-SUBQ PROVERA 10	6495534	MAY 15, 2020	DP	I-451	MAR 25, 2008
>ADD>	020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
>ADD>						I-430	JUL 16, 2007
>ADD>						PED	OCT 13, 2005
>ADD>						PED	JAN 16, 2008
>ADD>	021530 001	MELOXICAM;MOBIC	6184220	MAR 25, 2019	DP	I-430	JUL 16, 2007
>ADD>			6184220*PED	SEP 25, 2019		NCE	APR 13, 2005
>ADD>						PED	OCT 13, 2005
>ADD>						PED	JAN 16, 2008
>ADD>	021574 001	METFORMIN HYDROCHLORIDE;FORTAMET	6866866	MAR 17, 2021	DP		
>ADD>	021574 002	METFORMIN HYDROCHLORIDE;FORTAMET	6866866	MAR 17, 2021	DP		
	076863 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	APR 12, 2005
>ADD>	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	SEP 18, 2007	DP	D-95	FEB 15, 2008
>ADD>			4957745	SEP 18, 2007	DP U107		
>ADD>			5081154	SEP 18, 2007	DS		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	SEP 18, 2007	DP	D-95	FEB 15, 2008
>ADD>			4957745	SEP 18, 2007	DP U107		
>ADD>			5081154	SEP 18, 2007	DS		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	DP U107	D-95	FEB 15, 2008
>ADD>			5001161	SEP 18, 2007	DP		
>ADD>			5081154	SEP 18, 2007	DS		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	DP U107	D-95	FEB 15, 2008
>ADD>			5081154	SEP 18, 2007	DS U107		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>			5001161	SEP 18, 2007	DP U107		
>ADD>	021506 002	MICAFUNGIN SODIUM;MYCAMINE				NCE	MAR 16, 2010
>ADD>	020717 001	MODAFINIL;PROVIGIL				I-449	JAN 23, 2007
>ADD>	020717 002	MODAFINIL;PROVIGIL				I-449	JAN 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699	JAN 27, 2014	DP U625		
			6127353	OCT 03, 2017	DS DP		
			6723713	JAN 27, 2014	U625		
>ADD>	021067 001	MOMETASONE FUROATE;ASMANEX TWISTHALER				NP	MAR 30, 2008
	021204 001	NATEGLINIDE;STARLIX	RE34878	SEP 08, 2009			
			6844008	NOV 14, 2017	DP U214		
	021204 002	NATEGLINIDE;STARLIX	RE34878	SEP 08, 2009			
			6844008	NOV 14, 2017	DP U214		
>ADD>	019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	021706 001	OMEPRAZOLE;ZEGERID	5840737	JUL 16, 2016	DS U623		
			6489346	JUL 16, 2016	DS DP U624		
			6645988	JUL 16, 2016	DS DP U623		
			6780882	JUL 16, 2016	DS DP U624		
			6699885	JUL 16, 2016			
					U623		
					U624		
>ADD>	020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				PED	SEP 25, 2008
>ADD>						D-97	MAR 25, 2008
>ADD>	020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE				PED	SEP 25, 2008
>ADD>						D-97	MAR 25, 2008
	021759 001	OXALIPLATIN;ELOXATIN				NCE	AUG 09, 2007
						I-441	NOV 04, 2007
	021759 002	OXALIPLATIN;ELOXATIN				NCE	AUG 09, 2007
						I-441	NOV 04, 2007
	021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
	021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
	021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
	021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
>ADD>	021660 001	PACLITAXEL;ABRAXANE	6749868	FEB 22, 2013	DP	NP	JAN 07, 2008
>ADD>			6537579	FEB 22, 2013	U632		
>ADD>			6753006	FEB 22, 2013	DP		
>ADD>			6506405	FEB 22, 2013	DP U633		
>ADD>			6096331	FEB 22, 2013	DP U633		
>ADD>			5498421	MAR 12, 2013	DP U634		
>ADD>			5439686	FEB 22, 2013	DP		
	021756 001	PEGAPTANIB SODIUM;MACUGEN	6051698	SEP 17, 2012	DS		
			5919455	OCT 27, 2013	DS		
			5932462	AUG 03, 2016	DS		
			6113906	OCT 27, 2013	DS		
			6011020	JAN 04, 2017	DS		
			6426335	JUN 11, 2010	U622		
			6147204	JUN 11, 2010	DS		
>ADD>	021332 001	PRAMLINTIDE ACETATE;SYMLIN				NCE	MAR 16, 2010
	021446 001	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 002	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021446 003	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 004	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 005	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 006	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 007	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 008	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021511 001	RIBAVIRIN;COPEGUS				I-447	FEB 25, 2008
>ADD>	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	DS DP U329	I-453	FEB 28, 2008
>ADD>			5741803	APR 21, 2015	DS DP U628		
					U329		
					U628		
>ADD>	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5741803	APR 21, 2015	DS DP U329	I-453	FEB 28, 2008
>ADD>			5002953	AUG 30, 2008	DS DP U628		
					U329		
					U628		
>ADD>	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	DS DP U329	I-453	FEB 28, 2008
>ADD>			5741803	APR 21, 2015	DS DP U628		
					U329		
					U628		
>ADD>	021366 002	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
>ADD>	021366 003	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
>ADD>	021366 004	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
>ADD>	021366 005	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
	020645 001	SODIUM BENZOATE;AMMONUL				NDF	FEB 17, 2008
						ODE	FEB 17, 2012
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	021144 002	TELITHROMYCIN;KETEK				NCE	APR 01, 2009
>ADD>	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
>ADD>	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
>ADD>	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
>ADD>	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
	020505 001	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 002	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 003	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 004	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 005	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 006	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-41	AUG 11, 2007
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-41	AUG 11, 2007
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-41	AUG 11, 2007
>ADD>	021266 001	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
>ADD>	021266 002	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
>ADD>	021267 001	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
>ADD>	021630 001	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
	021060 001	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		
	021060 002	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		
	021060 003	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		
	021060 004	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of Patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm